Nicole Piazza
YOU?
Author Swipe
View article: Effect of Tofacitinib on One-Year Colectomy Risk in Anti-TNF Refractory Ulcerative Colitis: A Prospective Multicenter Italian Study
Effect of Tofacitinib on One-Year Colectomy Risk in Anti-TNF Refractory Ulcerative Colitis: A Prospective Multicenter Italian Study Open
View article: P981 Risankizumab, but not ustekinumab or vedolizumab, downregulates IL-23-induced mucosal pathogenic Th17 cells in patients with Crohn’s disease
P981 Risankizumab, but not ustekinumab or vedolizumab, downregulates IL-23-induced mucosal pathogenic Th17 cells in patients with Crohn’s disease Open
Background We recently described an interleukin(IL)-23-inducible pathogenic subset of CCR6+CXCR3-CCR5+ mucosal T helper (Th)17 cells (pTh17) infiltrating Crohn’s disease (CD) inflamed mucosa and specifically activated in response to Adhere…
View article: P1058 Safety and effectiveness of subcutaneous infliximab formulation in difficult-to-treat Crohn’s Disease patients with previous exposure to intravenous infliximab: A case-series
P1058 Safety and effectiveness of subcutaneous infliximab formulation in difficult-to-treat Crohn’s Disease patients with previous exposure to intravenous infliximab: A case-series Open
Background Despite the increased therapeutic armamentarium for Crohn’s Disease (CD), a relevant proportion of patients fail to respond to multiple therapies and ultimately require surgery. Intravenous (IV) infliximab (IFX) reinduction afte…
View article: P504 Prevalence of gastrointestinal infections in ulcerative colitis patients assessed with QIASTAT-DX® GASTROINTESTINAL PANEL 2
P504 Prevalence of gastrointestinal infections in ulcerative colitis patients assessed with QIASTAT-DX® GASTROINTESTINAL PANEL 2 Open
Background In inflammatory bowel disease (IBD), an acute clinical flare may be due to either disease exacerbation or an enteric infection. Thus, it is recommended to exclude infections before escalating IBD therapy. In this setting, conven…
View article: P612 Switching from intravenous to subcutaneous VEDOlizumab formulation in ulcerative colitis patients in clinical remission: the SVEDO Study, a multicenter IG-IBD study
P612 Switching from intravenous to subcutaneous VEDOlizumab formulation in ulcerative colitis patients in clinical remission: the SVEDO Study, a multicenter IG-IBD study Open
Background The administration of biologic drugs in inflammatory bowel diseases (IBD) is increasingly moving from intravenous to subcutaneous formulations. Limited data is available on the effectiveness of subcutaneous vedolizumab in patien…
View article: P921 Maintenance of clinical, biochemical and transmural remission in inflammatory bowel disease patients switching from intravenous to subcutaneous infliximab
P921 Maintenance of clinical, biochemical and transmural remission in inflammatory bowel disease patients switching from intravenous to subcutaneous infliximab Open
Background Subcutaneous (SC) infliximab (IFX) effectively maintains biochemical, clinical and endoscopic remission in inflammatory bowel disease (IBD) with a comparable safety profile to intravenous (IV) formulation. Transmural healing is …
View article: Superior predictive value of transmural over endoscopic severity for colectomy risk in ulcerative colitis: a multicentre prospective cohort study
Superior predictive value of transmural over endoscopic severity for colectomy risk in ulcerative colitis: a multicentre prospective cohort study Open
Background and Aims Endoscopic activity is associated with an increased risk of surgery in patients with ulcerative colitis [UC]. Transmural activity, as defined by Milan Ultrasound Criteria [MUC] > 6.2, reliably detects endoscopic acti…
View article: Switching from VEDOlizumab intravenous to subcutaneous formulation in ulcerative colitis patients in clinical remission: The SVEDO Study, an IG-IBD study
Switching from VEDOlizumab intravenous to subcutaneous formulation in ulcerative colitis patients in clinical remission: The SVEDO Study, an IG-IBD study Open
View article: SARS-CoV-2 infection in patients with inflammatory bowel disease: comparison between the first and second pandemic waves
SARS-CoV-2 infection in patients with inflammatory bowel disease: comparison between the first and second pandemic waves Open
View article: P423 Effect of tofacitinib on colectomy risk in anti TNF-alfa refractory ulcerative colitis
P423 Effect of tofacitinib on colectomy risk in anti TNF-alfa refractory ulcerative colitis Open
Background Tofacitinib is an oral janus kinase inhibitor (JAK) approved for patients with moderate to severe ulcerative colitis (UC) and either inadequate response or loss of response or intolerance to conventional or biologic therapy. The…
View article: P237 Superior predictive value of intestinal ultrasound over endoscopic severity for colectomy risk in patients with ulcerative colitis
P237 Superior predictive value of intestinal ultrasound over endoscopic severity for colectomy risk in patients with ulcerative colitis Open
Background Up to 15% of patients with ulcerative colitis (UC) do not respond to medical therapies and ultimately require colectomy for disease control. Baseline endoscopic severity and failure to achieve endoscopic healing, as defined by a…
View article: From advanced diagnosis to advanced resection in early neoplastic colorectal lesions: Never-ending and trending topics in the 2020s
From advanced diagnosis to advanced resection in early neoplastic colorectal lesions: Never-ending and trending topics in the 2020s Open
Colonoscopy represents the most widespread and effective tool for the prevention and treatment of early stage preneoplastic and neoplastic lesions in the panorama of cancer screening. In the world there are different approaches to the topi…
View article: Safety and clinical efficacy of the double switch from originator infliximab to biosimilars CT‐P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicenter cohort study
Safety and clinical efficacy of the double switch from originator infliximab to biosimilars CT‐P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicenter cohort study Open
Data regarding double switching from originator infliximab (IFX) to IFX biosimilars in inflammatory bowel diseases (IBDs) are lacking. The purpose of this study was to evaluate the safety and efficacy of switching from originator IFX to CT…
View article: Risk of COVID 19 in patients with inflammatory bowel diseases compared to a control population
Risk of COVID 19 in patients with inflammatory bowel diseases compared to a control population Open
View article: Dataset related to article "Contrast imaging techniques to diagnose hepatocellular carcinoma in cirrhotics outside regular surveillance."
Dataset related to article "Contrast imaging techniques to diagnose hepatocellular carcinoma in cirrhotics outside regular surveillance." Open
I NTRODUCTION AND AIM: The American Association for the Study of the Liver (AASLD) recommends contrast computerized tomography (CT-scan) and magnetic resonance (MRI) to diagnose hepatocellular carcinoma (HCC) arising in cirrhotic patients …
View article: Dataset related to article "Contrast imaging techniques to diagnose hepatocellular carcinoma in cirrhotics outside regular surveillance."
Dataset related to article "Contrast imaging techniques to diagnose hepatocellular carcinoma in cirrhotics outside regular surveillance." Open
I NTRODUCTION AND AIM: The American Association for the Study of the Liver (AASLD) recommends contrast computerized tomography (CT-scan) and magnetic resonance (MRI) to diagnose hepatocellular carcinoma (HCC) arising in cirrhotic patients …
View article: Patients with Inflammatory Bowel Disease Have a Lower Risk of COVID-19: A Case-Control Study from Lombardy, Italy
Patients with Inflammatory Bowel Disease Have a Lower Risk of COVID-19: A Case-Control Study from Lombardy, Italy Open
View article: Contrast imaging techniques to diagnose hepatocellular carcinoma in cirrhotics outside regular surveillance
Contrast imaging techniques to diagnose hepatocellular carcinoma in cirrhotics outside regular surveillance Open
A single contrast imaging technique showing a typical contrast pattern confidently identifies HCC also in cirrhotic patients with an incidental liver nodule, thereby reducing the need for FNB examinations.
View article: The Staging of Gastritis with the Olga System in the Italian Setting: Histological Features and Gastric Cancer Risk
The Staging of Gastritis with the Olga System in the Italian Setting: Histological Features and Gastric Cancer Risk Open